Novavax COVID-19 vaccine

Novavax COVID-19 Vaccine

Novavax logo

The Novavax COVID-19 vaccine, also known as NVX-CoV2373, is a protein subunit COVID-19 vaccine developed by Novavax, an American biotechnology company. The vaccine has been authorized for use in various countries to combat the COVID-19 pandemic.

Development

File:Novavax COVID-19 Vaccine.jpg

Novavax COVID-19 Vaccine

The development of the Novavax COVID-19 vaccine began in early 2020, following the identification of SARS-CoV-2, the virus responsible for COVID-19. The vaccine is based on Novavax's proprietary recombinant protein nanoparticle technology platform. The vaccine contains a modified form of the spike protein of SARS-CoV-2, which is designed to stimulate an immune response.

Efficacy

Clinical trials have shown that the Novavax COVID-19 vaccine has an efficacy rate of approximately 90%. This means that it reduces the risk of symptomatic COVID-19 infection by this percentage in vaccinated individuals compared to those who have not received the vaccine.

Authorization

The Novavax COVID-19 vaccine has been authorized for emergency use in various countries, including the United Kingdom, the European Union, and Canada. It is also under review for emergency use authorization by the U.S. Food and Drug Administration.

Side Effects

Common side effects of the Novavax COVID-19 vaccine include pain and swelling at the injection site, fatigue, headache, muscle pain, and chills. These side effects are typically mild and resolve within a few days.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• Novavax